How to Transform Biologics Development with Solutions for Biopharma Data Integration

July 16, 2025
Ada Yee

The biopharmaceutical industry is advancing at an unprecedented pace, driven by breakthroughs in monoclonal antibodies, gene therapies, and microbiome-based treatments. But with innovation comes complexity — especially when it comes to managing the vast and varied data generated across global R&D operations. For many organizations, the challenge of biopharma data integration is becoming a critical bottleneck in biologics and bioprocess development.^1–5

As companies expand their pipelines and global footprints, they often find themselves relying on outdated systems and fragmented workflows. Legacy electronic lab notebooks (ELNs), homegrown tools, and manual data transfers are still common across the industry.⁶ These systems may have served their purpose in the past, but today they create silos, slow down development, and make it nearly impossible to extract long-term value from scientific data.

Data Integration and Management Challenges: One Biopharma R&D Team’s Story

This was the reality for Ferring Pharmaceuticals, a global leader in reproductive medicine and pioneers in microbiome and gene therapies. As Ferring’s biologics programs grew — particularly in novel areas like FDA-approved microbiome replacement therapies — they recognized the urgent need for a unified, scalable data infrastructure that could support their expanding global R&D network, including cell line development (CLD), upstream processing (USP), downstream processing (DSP), and analytical groups. In 2021, Ferring launched a comprehensive search for a solution that could integrate biologics development workflows across sites in Israel, Germany, Switzerland, Denmark, and the United States. Their goal was to ensure data integrity, eliminate silos, and enable seamless collaboration across teams and technologies.

One of the biggest challenges they faced was the heterogeneity of data. Biologics development today involves a wide range of modalities, instruments, and technologies — including bioreactors, LC-MS, flow cytometers, imagers, and chromatography systems — each generating data in different formats. Without a centralized system, this diversity made it difficult to capture, process, and analyze data efficiently. Manual processes were not only time-consuming but also introduced compliance risks and limited the ability to scale. Ferring needed more than just a better ELN (electronic lab notebook), which still require time-consuming manual processes for data transfer, capture data in unstructured formats, and lack interoperability.⁶

Ferring needed a comprehensive data integration platform that captured structured data in a state-of-the art bioprocess data model, ensured traceability, and supported regulatory compliance.⁷ After an extensive evaluation process, they selected Genedata as the only off-the-shelf solution capable of meeting their complex requirements.

A Compliant & Scalable Solution for Biopharma R&D

Genedata provided Ferring with a centralized platform that integrated seamlessly with their existing IT infrastructure and lab instrumentation. It enabled automated data capture from diverse sources, supported structured workflows, and ensured full traceability across the development lifecycle. The platform’s flexibility also allowed Ferring to support novel applications, such as linking batch and donor data with in-house NGS pipelines for microbiome therapies.

Deployment was swift — within just three months, Genedata was fully operational across Ferring’s key sites. The impact was immediate: improved data quality, faster project timelines, and a significant reduction in manual effort. Most importantly, the platform gave Ferring the infrastructure they needed to scale their biologics programs in the future.

Ferring’s journey highlights a growing trend in the industry: the shift from fragmented, manual systems to integrated, scalable data infrastructure with a built-in data model that supports the full complexity of modern biopharma R&D. As bioprocess development becomes more data-intensive and globally distributed, companies that invest in robust data integration strategies will be better positioned to innovate, comply, and compete.

Want to see how Ferring made it happen?

Read the full customer success story to learn how they transformed their biologics development with Genedata Bioprocess.

References